- Press Release Distribution

Overcoming a newly recognized form of resistance to modern prostate cancer drugs

Some prostate tumors transition from being glandular to more nerve-like in response to drugs that block the androgen receptor; a new preclinical study examines the underlying mechanisms and uncovers a promising countermeasure

Overcoming a newly recognized form of resistance to modern prostate cancer drugs
( Cancer cells have an uncanny ability to evolve and adapt to overcome the treatments used against them.

While patient survival has been extended by modern drugs that block the production or action of male hormones that fuel prostate cancer -- androgen receptor inhibitors such as enzalutamide, apalutamide, darolutamide, and abiraterone -- eventually these drugs stop working. At that point, a patient's disease is considered incurable, or what doctors call metastatic, castration-resistant prostate cancer.

In a new study, a team of researchers led by Joshi Alumkal, M.D., who leads the prostate and genitourinary medical oncology section at the University of Michigan Rogel Cancer Center, uncovered new mechanisms underlying an important type of resistance called lineage plasticity. That's when castration-resistant prostate cancers undergo a deadly identity switch -- shifting from resembling glandular cells to neuroendocrine cells, which can behave more like small cell lung cancer.

The findings using human and mouse cell models and tissue biopsies from patients appear in Clinical Cancer Research and outline a promising path to overcoming this form of resistance: BET bromodomain inhibitors. These compounds work against bromodomain and extra-terminal (BET) proteins, which are involved in regulating gene activation.

"We know that treatment-emergent neuroendocrine prostate cancer is becoming more frequent as we use more newer and more potent androgen receptor inhibitors," Alumkal said. "Our prior work examining patients progressing on these newer androgen receptor inhibitors demonstrated that neuroendocrine prostate cancer was found in 17% of cases. By comparison, we find it in less than 1% of patients who have not undergone any form of androgen receptor inhibition. This strongly suggests that interference with androgen receptor function contributes to the increased numbers of treatment-emergent neuroendocrine prostate cancers we now see clinically."

Patients diagnosed with treatment-emergent neuroendocrine prostate cancer fare much worse than patients whose tumors remain adenocarcinomas -- glandular tumors -- surviving for only about one-third as long. Furthermore, there are very limited treatment options for patients with treatment-emergent neuroendocrine prostate cancer.

"We set out to understand how tumors shift their program to become neuroendocrine, the influence of androgen receptor inhibition on this process, and ways to block the switch to neuroendocrine prostate cancer," said Alumkal, who also co-leads of the translational and clinical research program at the U-M Rogel Cancer Center.

This line of investigation began when Alumkal was at the Knight Cancer Institute at Oregon Health & Science University and continued after his move to the U-M in 2019. The effort included a host of collaborators at other institutions, including scientists from the Dana-Farber Cancer Institute at Harvard University, the University of Washington, the Fred Hutchison Cancer Research Center, the Helen Diller Family Comprehensive Cancer Center at the University of California, San Francisco and the Memorial Sloan Kettering Cancer Center.

A promising countermeasure The major question the researchers sought to answer was whether modern prostate cancer drugs -- the new and more potent androgen receptor inhibitors -- might be so effective in shutting down the androgen receptor in some tumors that these drugs could actually promote the tumors' switch to become neuroendocrine tumors.

And the answer appears to be yes.

Through a series of experiments using laboratory cell models that were either sensitive to newer androgen receptor inhibitors or their counterpart cell models with acquired resistance, the research team found that androgen receptor inhibition was accentuating a neuroendocrine prostate cancer lineage plasticity program in the resistant cells -- an effect not achievable in the sensitive cells.

"Ultimately, we found that a critical difference that may allow the resistant cells to react differently and become more neuroendocrine is due to the way their DNA is organized and packaged," Alumkal said. "In the treatment-resistant cells, the chromatin is organized in a way that's more conducive to turning on that neuroendocrine program when the androgen receptor is blocked. It is as though the resistant cells have evolved to develop a rabbit hole through which they can change their identity and escape androgen receptor inhibition. We also found that high levels of a transcription factor called E2F1, which is involved in stemness and cell differentiation, is important for the resistant cells' ability to switch identities."

And it was this work to uncover the mechanisms giving rise to treatment-emergent neuroendocrine cancer that also pointed toward a potential solution: BET inhibitors.

Though E2F1 is not targetable directly, Alumkal's team determined that E2F1 cooperates with BET bromodomain proteins to turn on a neuroendocrine prostate cancer lineage plasticity program. Blocking BET bromodomain proteins in cell models stopped the activation of this program that drives the development of neuroendocrine prostate tumors, the research team found.

"When we treated a variety of treatment-emergent neuroendocrine prostate cancer cell lines with BET inhibitors, we greatly reduced the viability of these tumors, including tumors derived from patients," Alumkal said.

The study builds on a previous clinical trial by Alumkal and colleagues, which found a BET bromodomain inhibitor compound developed by Zenith Epigenetics, ZEN-3694, looked most active in castration-resistant prostate tumors from patients who had the lowest androgen receptor activity. Additionally, patients in the trial whose tumors didn't respond well to androgen receptor inhibitors prior to study enrollment appeared to have the most durable control with ZEN-3694, suggesting the most aggressive tumors may be particularly susceptible to BET bromodomain inhibition.

"We went back and determined that several patients from that ZEN-3694 clinical trial had treatment-emergent neuroendocrine prostate cancer," Alumkal said. "When we looked at the subset of those patients who did the best, they had the highest expression of E2F1 and the BET bromodomain protein BRD4, and the lowest expression of the androgen receptor."

"When we examined the neuroendocrine prostate cancer lineage plasticity program we identified in our cellular models, we found these same genes were highly turned on in the tumors from patients with treatment-emergent neuroendocrine prostate cancer who responded best to treatment with ZEN-3694," he added.

Ultimately, Alumkal said, the research points toward BET bromodomain inhibitors as potentially most beneficial for patients whose prostate cancer is no longer as dependent on the androgen receptor, and those with subsets of treatment-emergent neuroendocrine prostate cancer, particularly tumors in which transcription factor E2F1 may be playing an important role.

Building on the findings in the current study, a larger, international, randomized clinical trial is being planned to evaluate the effectiveness of ZEN-3694 with a particular focus on men whose tumors responded poorly to androgen receptor inhibitors -- tumors that may be less dependent on the androgen receptor.


Additional authors include Dae-Hwan Kim and Duanchen Sun, Chelsea Jenkins, Daniel J. Coleman, David Sampson, Xiangnan Guan, Joshua A. Urrutia, Jacob A. Schwartzman and Zheng Xia of the Knight Cancer Institute; William K. Storck, Katherine Welker Leng, Anbarasu Kumaraswamy, Eva S. Rodansky, Chao Zhang, Samuel K. Handelman, Jonathan Z. Sexton, Rahul Aggarwal, Armand Bankhead III, Arvind Rao and Joel A. Yates of U-M; Daniel E. Spratt of U-M and Case Western Reserve University; Himisha Beltran of the Dana-Farber Cancer Institute; Mark P. Labrecque, Colm Morrissey and Eva Corey of the University of Washington; Jared M. Lucas, Ilsa M. Coleman and Peter S. Nelson of the Fred Hutchinson Cancer Research Center; Wassim Abida of Memorial Sloan Kettering Cancer Center; Felix Y. Feng, Eric J. Small of the Helen Diller Family Comprehensive Cancer Center; and Emily M. Gesner, Sarah Attwell, Sanjay Lakhotia and Eric Campeau of Zenith Epigenetics.

Funding for the work includes the National Cancer Institute (R01CA251245, R01CA234715), the NCI Pacific Northwest Prostate Cancer SPORE (P50 CA097186); the NCI Michigan Prostate SPORE (P50 CA186786); the NCI Drug Resistance and Sensitivity Network (P50 CA186786-07S1, U54CA224079); Department of Defense Impact Award (W81XWH-16-1-0597) and Department of Defense Prostate Cancer Research Program Physician Research Award (W81XWH-17-1-0124), a Prostate Cancer Foundation Young Investigator Award, the Wayne D. Kuni and Joan E. Kuni Foundation; a U-M Rogel Scholars Award and Rogel Innovation Award/NCI (P30 CA046592); and a Sheppard Family Fund Sheppard Scholar Award. OHSU, UCSF and MSKCC received research funding from Zenith Epigenetics to conduct the industry-sponsored ZEN-3694 clinical trial.

Disclosures: Several members of the research team have received consulting income, honoraria and speakers' fees from pharmaceutical companies. OHSU, UCSF, and MSKCC have received research funding from Zenith Epigenetics to conduct the ZEN-3694 clinical trial. Co-authors Gesner, Attwell, Lakhotia and Campeau are employees of Zenith Epigenetics, which makes the study compound ZEN-3694.

Paper cited: "BET Bromodomain Inhibition Blocks an AR-Repressed, E2F1-Activated Treatment-Emergent Neuroendocrine Prostate Cancer Lineage Plasticity Program," Clinical Cancer Research. DOI: 10.1158/1078-0432.CCR-20-4968

[Attachments] See images for this press release:
Overcoming a newly recognized form of resistance to modern prostate cancer drugs


Will reduction in tau protein protect against Parkinson's and Lewy body dementias?

Will reduction in tau protein protect against Parkinsons and Lewy body dementias?
BIRMINGHAM, Ala. - Will a reduction in tau protein in brain neurons protect against Parkinson's disease and Lewy body dementias? A new study, published in the journal eNeuro, suggests the answer is no. If this is borne out, that result differs from Alzheimer's disease, where reducing endogenous tau levels in brain neurons is protective for multiple models of the disease -- which further suggests that the role of tau in the pathogenesis of Lewy body dementias is distinct from Alzheimer's disease. Both Parkinson's disease dementia and Lewy body dementia are characterized by intracellular aggregates of misfolded alpha-synuclein protein in brain neurons, and the two diseases together are the second most common cause of neurodegenerative dementia after ...

The end of Darwin's nightmare at Lake Victoria?

Lake Victoria, which came under the spotlight in 2004 by the documentary "Darwin's nightmare", is not only suffering from the introduction and commercialisation of the Nile perch. A study lead researchers from the University of Liège (Belgium) has highlighted other worrying phenomena, particularly climatic ones, which have an equally important impact on the quality of the lake's waters. Located in East Africa, just south of the Equator, Lake Victoria is the source of the Nile and is the largest tropical lake in the world. With a surface area of 68,800 km² (twice the size of Belgium), it is considered to be one of the largest water and fishery resources in East Africa, supporting more than 47 million people in the three neighbor countries ...

Study: Men doing more family caregiving could lower their risk of suicide

Colorado State University Professor of Psychology Silvia Sara Canetto has spent many years researching patterns and meanings of suicide by culture, trying to make sense of the variability in women's and men's suicide mortality around the world. Suicide rates are generally higher in men than in women, but not everywhere - which suggests cultural influences. Canetto and colleagues have completed a new study that provides insight into what may contribute to men's suicide vulnerability. The study tests Canetto's theory that men's suicide mortality ...

Researchers dig deeper into how cells transport their waste for recycling

Researchers dig deeper into how cells transport their waste for recycling
Scientists at Sanford Burnham Prebys have gained a deeper insight into the intricacies of autophagy, the process in which cells degrade and recycle cellular components. The findings, published in Current Biology, describe how the "trash bags" in a cell--called autophagosomes--are tagged to direct their movement to the cellular "recycling plants" where waste is processed. The research opens new paths to understanding the relationship between autophagy and age-related diseases such as cancer and neurological disorders. "Our latest study identifies how a chemical modification (phosphate-related ...

Organic farming could feed Europe by 2050

Organic farming could feed Europe by 2050
Food has become one of the major challenges of the 21st century. According to a study carried out by CNRS scientists1, an organic, sustainable, biodiversity-friendly agro-food system, could be implemented in Europe and would allow a balanced coexistence between agriculture and the environment. The scenario proposed is based on three levers. The first would involve a change in diet, with less consumption of animal products, making it possible to limit intensive livestock farming and eliminate feed imports. The second lever would require the application of the principles of agroecology, with the generalization of long, diversified crop rotation systems2 incorporating nitrogen-fixing legumes, making it possible to do without synthetic nitrogen fertilizers and ...

Assessing Racial, Ethnic disparities in access to COVID-19 vaccination sites

What The Study Did: Researchers reviewed access to COVID-19 vaccination sites in Brooklyn, the most populated borough in New York, to better understand disparities in vaccination. Authors: Natasha Williams, Ed.D., M.P.H., of the New York University Grossman School of Medicine in New York, is the corresponding author. To access the embargoed study: Visit our For The Media website at this link (doi:10.1001/jamanetworkopen.2021.13937) Editor's Note: The article includes funding/support disclosures. Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support. INFORMATION: Media advisory: The ...

COVID-19 in Spain

What The Study Did: Researchers describe the local transmission pattern of SARS-CoV-2 in Valencia, the third most populated city in Spain. Authors: Carolina Romero García, M.D., Ph.D., of the University General Hospital, European University, in Valencia, Spain, is the corresponding author. To access the embargoed study: Visit our For The Media website at this link (doi:10.1001/jamanetworkopen.2021.13818) Editor's Note: The article includes conflict of interest and funding/support disclosures. Please see ...

Pregnancy outcomes are affected by both maternal and paternal inflammatory disease

Karin Hellgren and colleagues examined pregnancy outcomes in relation to disease activity and antirheumatic treatment strategies in women with RA. This matched cohort study from Sweden and Denmark explored the associations between maternal RA and pre-term birth (PTB), or delivering babies small for gestational age (SGA)in relation to the mother's disease activity and use of antirheumatic treatment before and during pregnancy. Using national medical birth registers and rheumatology registers, the authors looked at1739pregnancies in women with RA, and 17,390 control pregnancies in the general population. Overall, women with RA had an increased likelihood of having pre-term and small babies. High ...

Passive smoking and air pollution -- links to arthritis development and poor response to therapy

RA is an inflammatory autoimmune disease that causes pain, swelling and stiffness in the joints. It can also cause fatigue, and the underlying inflammation may affect other body systems. It is more common in women than in men. To date, active smoking has been the most reproducibly reported risk factor for a type of RA called anti-citrullinated protein antibody (ACPA) positive RA-particularly in people who carry the HLA-DRB1-shared epitope alleles. Nguyen and colleagues set out to investigate the relationship between passive smoking and the risk of developing RA in a large prospective cohort of healthy French women. The E3N-EPIC (Etude Epidémiologique au prèsdes femmes de la Mutuelle générale de l'Education ...

Impact of a national tender system on biologic and targeted drug costs in Norway

At the 2021 EULAR congress, Brkic and colleagues presented data from people with rheumatoid arthritis (RA)treated at Norwegian rheumatology outpatient clinics between 2010 and 2019. The project BioRheuma (BIOlogic treatment of patients suffering from inflammatory RHEUMAtic disorders in Norway) aimed to monitor people receiving b/tsDMARDs. Anonymized data files from10 participating centres were merged and analyzed over a 10-year period to show the annual total b/tsDMARD cost, as well as the mean cost per patient for all current users, for all those who started treatment, and for initiating patients naïve to b/tsDMARDs. The cost was calculated based on price offers given at the annual tender process for the different years. The number of registered RA patients in the databases increased ...


Scientists model 'true prevalence' of COVID-19 throughout pandemic

New breakthrough to help immune systems in the fight against cancer

Through the thin-film glass, researchers spot a new liquid phase

Administering opioids to pregnant mice alters behavior and gene expression in offspring

Brain's 'memory center' needed to recognize image sequences but not single sights

Safety of second dose of mRNA COVID-19 vaccines after first-dose allergic reactions

Changes in disparities in access to care, health after Medicare eligibility

Use of high-risk medications among lonely older adults

65+ and lonely? Don't talk to your doctor about another prescription

Exosome formulation developed to deliver antibodies for choroidal neovascularization therapy

Second COVID-19 mRNA vaccine dose found safe following allergic reactions to first dose

Plant root-associated bacteria preferentially colonize their native host-plant roots

Rare inherited variants in previously unsuspected genes may confer significant risk for autism

International experts call for a unified public health response to NAFLD and NASH epidemic

International collaboration of scientists rewrite the rulebook of flowering plant genetics

Improving air quality reduces dementia risk, multiple studies suggest

Misplaced trust: When trust in science fosters pseudoscience

Two types of blood pressure meds prevent heart events equally, but side effects differ

New statement provides path to include ethnicity, ancestry, race in genomic research

Among effective antihypertensive drugs, less popular choice is slightly safer

Juicy past of favorite Okinawan fruit revealed

Anticipate a resurgence of respiratory viruses in young children

Anxiety, depression, burnout rising as college students prepare to return to campus

Goal-setting and positive parent-child relationships reduce risk of youth vaping

New research identifies cancer types with little survival improvements in adolescents and young adul

Oncotarget: Replication-stress sensitivity in breast cancer cells

Oncotarget: TERT and its binding protein: overexpression of GABPA/B in gliomas

Development of a novel technology to check body temperature with smartphone camera

The mechanics of puncture finally explained

Extreme heat, dry summers main cause of tree death in Colorado's subalpine forests

[] Overcoming a newly recognized form of resistance to modern prostate cancer drugs
Some prostate tumors transition from being glandular to more nerve-like in response to drugs that block the androgen receptor; a new preclinical study examines the underlying mechanisms and uncovers a promising countermeasure